Sanoman: I know that AVII was working on utilizing antisense morpholinos to combat transplant rejection. But they have moved their anti-viral platform to the forefront and everything else has fallen to the wayside.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.